[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Wang SL, Liao ZX, Liu XF, Yu ZH, Gu DZ, Qian TN, Song YW, Jin J, Wang WH, Li YX: Primary early-stage intestinal and colonic non-Hodgkin's lymphoma: clinical features, management, and outcome of 37 patients. World J Gastroenterol; 2005 Oct 7;11(37):5905-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary early-stage intestinal and colonic non-Hodgkin's lymphoma: clinical features, management, and outcome of 37 patients.
  • AIM: To analyze the clinical features, management, and outcome of treatment of patients with primary intestinal and colonic non-Hodgkin's lymphoma (PICL).
  • Thirty-five patients underwent surgery (including 31 with complete resection), 22 received postoperative chemotherapy or radiotherapy or both.
  • Two patients with rectal tumors underwent biopsy and chemotherapy with or without radiotherapy.
  • In univariate analysis, multiple-modality treatment was associated with a better DFS rate compared to single treatment (P = 0.001).
  • While age, tumor size, tumor site, stage, histology, or extent of surgery were not associated with OS and DFS, use of adjuvant chemotherapy significantly improved DFS (P = 0.031) for the 31 patients who underwent complete resection.
  • Additional radiotherapy combined with chemo-therapy led to a longer survival than chemotherapy alone in six patients with gross residual disease after surgery or biopsy.
  • CONCLUSION: Combined surgery and chemotherapy is recommended for treatment of patients with PICL.
  • [MeSH-major] Colonic Neoplasms / pathology. Intestinal Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Survival Analysis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270408.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4479699
  •  go-up   go-down


2. Bairey O, Ruchlemer R, Shpilberg O: Non-Hodgkin's lymphomas of the colon. Isr Med Assoc J; 2006 Dec;8(12):832-5
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphomas of the colon.
  • BACKGROUND: Non-Hodgkin's lymphoma of the colon is a rare and consequently poorly studied extranodal lymphoma.
  • Most of the previous publications used old pathologic classifications and old diagnostic and treatment approaches.
  • OBJECTIVE: To examine the clinical presentation, pathologic classification, treatment and outcome of patients with NHL of the colon.
  • METHODS: A retrospective study was performed of all patients with NHL and involvement of the colon in two medical centers.
  • RESULTS: Fourteen patients had primary involvement and 3 secondary.
  • Aggressive histology was found in 12 patients: diffuse large B cell lymphoma in 11 and peripheral T cell lymphoma in 1.
  • Three patients had mantle cell lymphoma and two had indolent lymphomas: mucosa-associated lymphoid tissue (n=l) and small lymphocytic (n=l).
  • Disease stage influenced prognosis; six of seven patients with limited-stage DLBCL who received aggressive chemotherapy achieved complete remission and enjoyed prolonged survival, whereas patients with aggressive disseminated disease had resistant disease and poor survival (median 8 months).
  • CONCLUSIONS: Most colonic lymphomas are aggressive B cell lymphomas.
  • Those with limited-stage disease when treated with aggressive chemotherapy may enjoy prolonged survival.
  • [MeSH-major] Colorectal Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17214096.001).
  • [ISSN] 1565-1088
  • [Journal-full-title] The Israel Medical Association journal : IMAJ
  • [ISO-abbreviation] Isr. Med. Assoc. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Israel
  •  go-up   go-down


3. Tauro LF, Furtado HW, Aithala PS, D'Souza CS, George C, Vishnumoorthy SH: Primary lymphoma of the colon. Saudi J Gastroenterol; 2009 Oct-Dec;15(4):279-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary lymphoma of the colon.
  • Primary lymphoma of the colon is a rare tumor of the gastrointestinal (GI) tract and comprises only 0.2-1.2% of all colonic malignancies.
  • The most common variety of colonic lymphoma is non-Hodgkin's lymphoma (NHL).
  • The GI tract is the most frequently involved site, accounting for 30-40% of all extra nodal lymphomas, approximately 4-20% of which are NHL.
  • Therapeutic approaches described in two subsets include: Radical tumor resection (hemicolectomy) plus multi-agent chemotherapy (polychemotherapy) in early stage patients, biopsy plus multidrug chemotherapy in advanced stage patients.
  • Radiotherapy is reserved for specific cases; surgery alone can be considered as an adequate treatment for patients with low-grade NHL disease that does not infiltrate beyond the sub mucosa.
  • Although resection plays an important role in the local control of the disease and in preventing bleeding and/or perforation, it rarely eradicates the lymphoma by itself.
  • Those with limited stage disease may enjoy prolonged survival when treated with aggressive chemotherapy.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Haematologica. 2000 Apr;85(4):372-80 [10756362.001]
  • [Cites] Am J Surg. 2009 Jan;197(1):e11-2 [18723150.001]
  • [Cites] Int Surg. 2001 Jan-Mar;86(1):20-5 [11890335.001]
  • [Cites] Ann Oncol. 1993 Dec;4(10):831-7 [8117602.001]
  • [Cites] J Clin Gastroenterol. 1994 Jun;18(4):291-7 [8071513.001]
  • [Cites] Leuk Lymphoma. 1995 Nov;19(5-6):461-6 [8590847.001]
  • [Cites] Haematologica. 1997 May-Jun;82(3):305-8 [9234576.001]
  • [Cites] Yonsei Med J. 2006 Feb 28;47(1):22-33 [16502482.001]
  • [Cites] Colorectal Dis. 2006 Sep;8(7):586-91 [16919111.001]
  • [Cites] Dis Colon Rectum. 2006 Oct;49(10):1546-51 [16990978.001]
  • [Cites] Isr Med Assoc J. 2006 Dec;8(12):832-5 [17214096.001]
  • [Cites] Am Surg. 2008 Mar;74(3):214-6 [18376684.001]
  • [Cites] J Surg Oncol. 2008 Nov 1;98(6):444-7 [18668640.001]
  • [Cites] Gastrointest Endosc. 2008 Nov;68(5):1005-6; discussion 1006 [18565526.001]
  • [Cites] J Surg Oncol. 2000 Aug;74(4):257-62 [10962456.001]
  • (PMID = 19794280.001).
  • [ISSN] 1998-4049
  • [Journal-full-title] Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association
  • [ISO-abbreviation] Saudi J Gastroenterol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Saudi Arabia
  • [Other-IDs] NLM/ PMC2981851
  •  go-up   go-down


Advertisement
4. Matković S, Jelić S, Manojlović N, Milanović N: Non-Hodgkin's lymphomas with primary localization in large bowel and rectum. Med Sci Monit; 2000 Jan-Feb;6(1):68-74

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphomas with primary localization in large bowel and rectum.
  • From 1989, at the Department of Medical Oncology of the Institute for Oncology and Radiology in Belgrade, seven patients with primary NHL of large bowel and rectum have been observed and treated, 3 males and 4 females.
  • Five patients had lymphoma localized in cecoascedental part of colon (2 centroblastic, 1 lymphoplasmocytic, 1 Burkitt and 1 Burkitt's like), 1 patient had it in the transversal part of colon (centroblastic), and one in the rectum (diffuse centrocytic).
  • By further investigation, in 2 cases with localization within transversal part of colon and rectum no other sites of NHL were found.
  • Out of 5 patients with localization within cecum or ascendent part of colon, in 2 cases with Burkitt/Burkitt-like histology retroperitoneal lymphadenopathy were found, one female had NHL central propagation, and the other one lymphoma generalization.
  • Both patients had early death from lymphoma.
  • The remaining three patients following chemotherapy with the ProMACE regimen (as they too had a post laparotomy stage II disease) achieved a complete response lasting for 36+, 41+ and 66+ months.
  • Since the median survival in our group of patients is at the moment 41+ months and the median has not yet been reached, our experience does not confirm literature data claiming bad prognosis of primary NHL of the colon and rectum.
  • A long disease free survival can be obtained in these patients either with surgery only or surgery + chemotherapy, depending on disease stage and possibly initial topographic localization.
  • [MeSH-major] Colonic Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology. Rectal Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11208286.001).
  • [ISSN] 1234-1010
  • [Journal-full-title] Medical science monitor : international medical journal of experimental and clinical research
  • [ISO-abbreviation] Med. Sci. Monit.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


5. Giunta R, Marfella MA, Maffei A, Lucivero G: Herpes zoster infection and Ogilvie's syndrome in non-Hodgkin's lymphoma with hypogammaglobulinemia. Ann Ital Med Int; 2001 Jan-Mar;16(1):50-3
MedlinePlus Health Information. consumer health - Shingles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Herpes zoster infection and Ogilvie's syndrome in non-Hodgkin's lymphoma with hypogammaglobulinemia.
  • The case of a 43-year-old male with non-Hodgkin's lymphoma (stage IV B), and hypo-IgG and IgM, who developed acute colonic pseudo-obstruction or Ogilvie's syndrome during chemotherapy, is presented.
  • The simultaneous occurrence of a unilateral segmental vesicular rash indicative of herpes zoster infection suggests an etiopathogenetic relationship between the colonic pseudo-obstruction and herpetic involvement of the motor celiac sympathetic ganglia.
  • The rapid resolution of the abdominal dilation and the functional recovery from the colonic pseudo-obstruction after anti-viral therapy is also consistent with the diagnostic hypothesis.
  • [MeSH-major] Agammaglobulinemia / complications. Colonic Pseudo-Obstruction / complications. Herpes Zoster / complications. Lymphoma, Large B-Cell, Diffuse / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11688352.001).
  • [ISSN] 0393-9340
  • [Journal-full-title] Annali italiani di medicina interna : organo ufficiale della Società italiana di medicina interna
  • [ISO-abbreviation] Ann. Ital. Med. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


6. Doolabh N, Anthony T, Simmang C, Bieligk S, Lee E, Huber P, Hughes R, Turnage R: Primary colonic lymphoma. J Surg Oncol; 2000 Aug;74(4):257-62
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary colonic lymphoma.
  • BACKGROUND AND OBJECTIVES: The colon is a rare location for gastrointestinal non-Hodgkin's lymphoma (NHL).
  • This study was undertaken to identify risk factors, presentation, treatment, and prognosis for primary colonic lymphoma (PCL) through review of a large tertiary care hospital system experience.
  • METHODS: A retrospective review of all patients with colonic malignancy and NHL was performed using pathology and cancer registry databases from January 1989 to December 1998.
  • Criteria for inclusion were no evidence of extraperitoneal disease, no leukemic or lymphomatous abnormalities in the blood, and disease confined to the colon.
  • They represented 1.4% of all NHL, 14% of gastrointestinal NHL and 0.9% of all colonic malignancies diagnosed during this period.
  • Six of 7 patients received adjuvant chemotherapy.
  • CONCLUSIONS: The colon is a rare location for NHL.
  • Patients' frequently present with non-specific abdominal pain, this leads to lengthy delays in diagnosis.
  • Surgery is the most widely utilized form of therapy.
  • Although adjuvant therapy is frequently utilized, its' impact on survival is unclear.
  • [MeSH-major] Colonic Neoplasms / epidemiology. Colonic Neoplasms / pathology. Lymphoma, Non-Hodgkin / epidemiology. Lymphoma, Non-Hodgkin / pathology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10962456.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


7. Villanueva-Sáenz E, Alvarez-Tostado Fernández JF, Martínez Hernández-Magro P, Valdés-Ovalle M, Peña Ruiz-Esparza JP: [Colonic primary lymphoma]. Rev Gastroenterol Mex; 2002 Jan-Mar;67(1):28-33
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Colonic primary lymphoma].
  • [Transliterated title] Linfoma primario de colon.
  • Primary colon lymphomas (PCL) are very rare tumors of the gastrointestinal tract, and represent 0.2-0.5% of all colon primary tumors.
  • Almost all are non-Hodgkin's lymphomas; first however, one must discard lymph node origin.
  • Treatment of choice is surgical, plus adjuvant chemotherapy.
  • METHOD: Review two of cases of cecum lymphomas and their treatment.
  • RESULTS: We inform the cases of two patients with the diagnosis of cecum lymphoma.
  • Both patients received chemotherapy and remain free of disease at 1.5 and 5 years of follow-up.
  • CONCLUSIONS: Primary colon lymphomas are very uncommon gastrointestinal tumors, with cecum localization as one of the most frequent sites of presentation in the colon.
  • Treatment of choice must be surgical, with chemotherapy as an adjuvant therapy to improve survival.
  • [MeSH-major] Colonic Neoplasms / therapy. Lymphoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12066428.001).
  • [ISSN] 0375-0906
  • [Journal-full-title] Revista de gastroenterología de México
  • [ISO-abbreviation] Rev Gastroenterol Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


8. Kim HC, Nam SW, Cho YK, Jeong HJ, Kim SI, Kim SH, An CM, Kim IH, Kim SW, Lee SO, Lee ST: [A case of Non-Hodgkin's lymphoma in a patient with Crohn's disease]. Korean J Gastroenterol; 2006 Mar;47(3):233-7
MedlinePlus Health Information. consumer health - Crohn's Disease.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of Non-Hodgkin's lymphoma in a patient with Crohn's disease].
  • Although adenocarcinoma is a well known complication of chronic inflammatory bowel disease, primary gastrointestinal lymphoma occurring in Crohn's disease is rare.
  • A 40-year-old man with 10 year-history of Crohn's disease had multiple longitudinal ulcerative lesions on descending colon in follow-up colonoscopic examination.
  • Microscopic examination of proximal descending colon revealed peripheral T cell lymphoma and other site of the descending colon was consistent with Crohn's disease.
  • The patient reached complete remission of malignant lymphoma after three cycles of combined chemotherapy.
  • He has been well for 10 months with sulfasalazine maintenance therapy but was admitted to the hospital due to spontaneous bowel perforation of ascending colon.
  • To the best of our knowledge, this is the first case of Non-Hodgkin's lymphoma complicating Crohn's disease in Korea which was confirmed by immunohistochemical studies.
  • [MeSH-major] Colonic Neoplasms / complications. Crohn Disease / complications. Lymphoma, T-Cell / complications

  • Genetic Alliance. consumer health - Crohn Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16554679.001).
  • [ISSN] 1598-9992
  • [Journal-full-title] The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
  • [ISO-abbreviation] Korean J Gastroenterol
  • [Language] kor
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


9. Kumar S, Fend F, Quintanilla-Martinez L, Kingma DW, Sorbara L, Raffeld M, Banks PM, Jaffe ES: Epstein-Barr virus-positive primary gastrointestinal Hodgkin's disease: association with inflammatory bowel disease and immunosuppression. Am J Surg Pathol; 2000 Jan;24(1):66-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epstein-Barr virus-positive primary gastrointestinal Hodgkin's disease: association with inflammatory bowel disease and immunosuppression.
  • Inflammatory bowel disease (IBD) is associated with an increased risk of lymphoma, which is usually extraintestinal but sometimes may involve the diseased bowel itself.
  • Most lymphomas described in this setting are of non-Hodgkin's type, but rare cases of Hodgkin's disease (HD) have been reported.
  • We describe the clinicopathologic and molecular features of four patients with primary gastrointestinal HD.
  • Three patients had preexistent Crohn's disease (CD), for which two of them had received immunosuppressive therapy.
  • The fourth patient had a longstanding history of diverticulitis and myasthenia gravis and was receiving immunosuppressive therapy for the latter.
  • Two patients received chemotherapy, one of whom was dead at 9 months, whereas the other has no evidence of disease at 25 months' follow-up.
  • The patient with IE disease did not receive any therapy because only a few microscopic foci of disease were present and is also without any evidence of disease at 17 months.
  • In two cases, laser capture microdissection was used to isolate individual RS and Hodgkin's cells, which contained rearranged immunoglobulin genes, confirming a B-cell genotype.
  • Disordered immunoregulation inherent to CD and immunosuppressive therapy for the latter may contribute to its development.
  • [MeSH-major] Colonic Neoplasms / pathology. Crohn Disease / complications. Herpesvirus 4, Human / isolation & purification. Hodgkin Disease / complications. Ileal Neoplasms / pathology. Immunosuppression / adverse effects
  • [MeSH-minor] Adult. Aged. Biopsy. Colectomy. Colon / pathology. Colon, Sigmoid / pathology. Female. Follow-Up Studies. Humans. Ileum / pathology. Immunophenotyping. In Situ Hybridization. Lymphatic Metastasis. Male. Polymerase Chain Reaction. Reed-Sternberg Cells. Time Factors

  • MedlinePlus Health Information. consumer health - Crohn's Disease.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10632489.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] UNITED STATES
  •  go-up   go-down


10. Schwartz LK, Kim MK, Coleman M, Lichtiger S, Chadburn A, Scherl E: Case report: lymphoma arising in an ileal pouch anal anastomosis after immunomodulatory therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol; 2006 Aug;4(8):1030-4
Hazardous Substances Data Bank. CYCLOSPORIN A .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: lymphoma arising in an ileal pouch anal anastomosis after immunomodulatory therapy for inflammatory bowel disease.
  • The risk of lymphoma in inflammatory bowel disease (IBD) has raised concerns regarding the lymphogenic potential of immunomodulatory therapy.
  • The link between immunosuppressive therapy and lymphoma risk is well established in patients with solid organ transplantations.
  • In this report, we describe a case of EBV-positive non-Hodgkin's lymphoma arising in the ileal pouch of a patient with ulcerative colitis.
  • [MeSH-major] Anastomosis, Surgical. Colitis, Ulcerative / drug therapy. Colonic Pouches. Ileum / surgery. Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] 6-Mercaptopurine / therapeutic use. Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclosporine / therapeutic use. Glucocorticoids / therapeutic use. Humans. Immunosuppressive Agents / therapeutic use. Male. Prednisone / therapeutic use

  • MedlinePlus Health Information. consumer health - Ulcerative Colitis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Gastroenterol Hepatol. 2007 Apr;5(4):521; author reply 521-2 [17445756.001]
  • [CommentOn] Clin Gastroenterol Hepatol. 2006 Aug;4(8):976-8 [16880119.001]
  • (PMID = 16854631.001).
  • [ISSN] 1542-3565
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glucocorticoids; 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; E7WED276I5 / 6-Mercaptopurine; VB0R961HZT / Prednisone
  •  go-up   go-down


11. Genovese AM, Fedele F, Barbera A, Fonti MT, Rossitto M, De Jesi F, Ciccolo A: [Primary non-Hodgkin's lymphoma of the colon: a rare but possible location. Therapeutic approach. Description of a clinical case and review of the literature]. Minerva Chir; 2002 Apr;57(2):217-20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary non-Hodgkin's lymphoma of the colon: a rare but possible location. Therapeutic approach. Description of a clinical case and review of the literature].
  • [Transliterated title] Linfoma non-Hodgkin primitivo del colon: una rara, ma possibile localizzazione. Iter terapeutico. Descrizione di un caso clinico e revisione della letteratura.
  • On the basis of a case of large cell, highly malignant, non-Hodgkin's lymphoma of the colon, the authors describe the special features of this rare location; the general aspects of this rare pathology of the colon are then considered.
  • The clinical case relates to a large cell, highly malignant, non-Hodgkin's colic lymphoma located in the caecum at two thirds proximally of the ascending colon of which it occupies half the lumen.
  • In disaccord with certain literature reports, surgical treatment was considered by the authors the key to the therapeutic approach.
  • Surgical exeresis should be as radical as possible to permit complementary therapies (chemotherapy and radio-therapy) to act with most effectiveness and thus offer the patient a better life.
  • [MeSH-major] Lymphoma, Large-Cell, Immunoblastic / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11941297.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] ita
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 5
  •  go-up   go-down


12. Urahashi T, Miura O, Otawa R, Kawano T, Matsusaki K, Toda T, Minamisono Y, Nagasaki S: En bloc resection for primary non-Hodgkin's lymphoma of the descending colon with massive extension into the neighboring organs. Hepatogastroenterology; 2007 Jan-Feb;54(73):144-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] En bloc resection for primary non-Hodgkin's lymphoma of the descending colon with massive extension into the neighboring organs.
  • A 79-year-old female who was surgically treated and received adjuvant chemotherapy for primary non-Hodgkin's lymphoma of the descending colon with massive extension into the pancreatic tail, spleen, and left kidney is herein reported.
  • The patient had acute colonic obstruction and an urgent laparotomy was performed because endoscopic decompression using a transnasal ileus tube could not be done.
  • [MeSH-major] Colonic Neoplasms / pathology. Colonic Neoplasms / surgery. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / surgery
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Colonic Diseases / etiology. Colonoscopy. Female. Humans. Immunohistochemistry. Intestinal Obstruction / etiology. Lymphocytes / pathology. Neoplasm Invasiveness

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17419249.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


13. Farrell RJ, Ang Y, Kileen P, O'Briain DS, Kelleher D, Keeling PW, Weir DG: Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut; 2000 Oct;47(4):514-9
MedlinePlus Health Information. consumer health - Irritable Bowel Syndrome.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased incidence of non-Hodgkin's lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low.
  • BACKGROUND: There is concern that the incidence of non-Hodgkin's lymphoma (NHL) will rise with increasing use of immunosuppressive therapy.
  • AIMS: Our aim was to determine the risk of NHL in a large cohort of patients with inflammatory bowel disease (IBD), and to study the association between IBD, NHL, and immunosuppressive therapy.
  • METHODS: We studied 782 IBD patients (238 of whom received immunosuppressive therapy) who attended our medical centre between 1990 and 1999 (median follow up 8.0 years).
  • RESULTS: There were four cases of NHL in our IBD cohort (SIR 31.2; 95% CI 2.0-85; p=0.0001), all of whom had received immunosuppressive therapy: azathioprine (n=2), methotrexate (n=1), and methotrexate and cyclosporin (n=1).
  • Our immunosuppressive group had a significantly (59 times) higher risk of NHL compared with that expected in the general population (p=0.0001).
  • Three cases were intestinal NHL and one was mesenteric.
  • Mean age at NHL diagnosis was 49 years, mean duration of IBD at the time of NHL diagnosis was 3.1 years, and mean duration between initiation of immunosuppressive therapy and diagnosis of NHL was 20 months.
  • CONCLUSIONS: Although underlying IBD may be a causal factor in the development of intestinal NHL, our experience suggests that immunosuppressive drugs can significantly increase the risk of NHL in IBD.
  • This must be weighed against the improved quality of life and clinical benefit immunosuppressive therapy provides for IBD patients.
  • [MeSH-major] Colonic Diseases, Functional / drug therapy. Immunosuppressive Agents / adverse effects. Intestinal Neoplasms / epidemiology. Lymphoma, Non-Hodgkin / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1992 Mar 1;69(5):1119-23 [1739911.001]
  • [Cites] Cancer. 1991 Apr 1;67(7):2015-9 [2004319.001]
  • [Cites] J Rheumatol. 1992 Sep;19(9):1462-5 [1433017.001]
  • [Cites] J Natl Cancer Inst. 1993 Feb 17;85(4):307-11 [8426374.001]
  • [Cites] N Engl J Med. 1993 May 6;328(18):1317-21 [8385742.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):571-4 [8102718.001]
  • [Cites] Lancet. 1994 May 21;343(8908):1249-52 [7910274.001]
  • [Cites] Gastroenterology. 1994 Dec;107(6):1675-9 [7958678.001]
  • [Cites] Br J Surg. 1961 Jul;49:50-3 [13881391.001]
  • [Cites] Gastroenterology. 1963 Mar;44:342-7 [13986689.001]
  • [Cites] Gut. 1964 Feb;5:1-22 [14127503.001]
  • [Cites] J Rheumatol. 1991 Nov;18(11):1741-3 [1787499.001]
  • [Cites] Gut. 1995 Feb;36(2):306-10 [7883235.001]
  • [Cites] Lancet. 1996 Jan 27;347(8996):215-9 [8551879.001]
  • [Cites] Leuk Lymphoma. 1995 Apr;17(3-4):255-62 [8580794.001]
  • [Cites] Am J Gastroenterol. 1996 Mar;91(3):423-33 [8633486.001]
  • [Cites] Am J Surg Pathol. 1996 Aug;20(8):1024-31 [8712289.001]
  • [Cites] Br J Rheumatol. 1996 Aug;35(8):738-45 [8761185.001]
  • [Cites] Arthritis Rheum. 1997 Oct;40(10):1843-51 [9336420.001]
  • [Cites] Korean J Intern Med. 1997 Jun;12(2):238-41 [9439161.001]
  • [Cites] J Intern Med. 1998 Dec;244(6):537-41 [9893108.001]
  • [Cites] Am J Gastroenterol. 1999 Jun;94(6):1643-9 [10364038.001]
  • [Cites] Gastroenterology. 1999 Dec;117(6):1433-7 [10579985.001]
  • [Cites] Arch Surg. 1966 Aug;93(2):215-25 [5330514.001]
  • [Cites] Am J Dig Dis. 1968 Oct;13(10):910-7 [4878622.001]
  • [Cites] Ann Surg. 1969 Aug;170(2):232-8 [5796708.001]
  • [Cites] Cancer. 1972 Jan;29(1):252-60 [5007387.001]
  • [Cites] JAMA. 1975 Apr 28;232(4):359-62 [1054764.001]
  • [Cites] Br J Surg. 1976 Jul;63(7):542-5 [953449.001]
  • [Cites] J Chronic Dis. 1978;31(11):691-6 [730824.001]
  • [Cites] Br Med J. 1979 Dec 8;2(6203):1461-6 [393355.001]
  • [Cites] Proc Natl Acad Sci U S A. 1980 Jan;77(1):588-92 [6965794.001]
  • [Cites] Am J Gastroenterol. 1983 May;78(5):316 [6687782.001]
  • [Cites] N Engl J Med. 1984 Feb 23;310(8):477-82 [6363929.001]
  • [Cites] N Engl J Med. 1984 Aug 30;311(9):565-70 [6611504.001]
  • [Cites] Cancer. 1985 Mar 1;55(5):1060-73 [3881161.001]
  • [Cites] Am J Med. 1985 Jan 21;78(1A):44-9 [3970040.001]
  • [Cites] Cancer. 1985 Dec 15;56(12):2914-21 [4052961.001]
  • [Cites] Ann Intern Med. 1989 Oct 15;111(8):641-9 [2802419.001]
  • [Cites] J Autoimmun. 1989 Oct;2(5):723-31 [2679624.001]
  • [Cites] Histopathology. 1989 Oct;15(4):325-37 [2680870.001]
  • [Cites] Gastroenterol Clin Biol. 1990;14(6-7):548-54 [2397863.001]
  • [Cites] N Engl J Med. 1990 Nov 1;323(18):1228-33 [2215606.001]
  • [CommentIn] Gut. 2000 Oct;47(4):462-3 [10986202.001]
  • (PMID = 10986211.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] ENGLAND
  • [Chemical-registry-number] 0 / Immunosuppressive Agents
  • [Other-IDs] NLM/ PMC1728075
  •  go-up   go-down


14. Stanojević GZ, Stojanović MP, Stojanović MM, Krivokapić Z, Jovanović MM, Katić VV, Jeremić MM, Branković BR: Non-Hodgkin's lymphomas of the large bowel-clinical characteristics, prognostic factors and survival. Acta Chir Iugosl; 2008;55(3):109-14

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphomas of the large bowel-clinical characteristics, prognostic factors and survival.
  • The aims of this study were to review the clinical presentation of non-Hodgkin's lymphomas of the large bowel, to analyze the prognostic factors using univariate and multivariate methods, as well as the overall survival.
  • The following clinical information such as age, gender, symptoms, tumor localization, operation performed, histology grade, stage of disease, and adjuvant chemotherapy was obtained.
  • Overall mean survival time was 41.91 months.
  • According to the univariete analysis, the factors influencing overall survival rate was operation type (elective and emergent).
  • Tumor stage and operation type were independent prognostic factors for survival, as determined by multivariate analysis.
  • Our results showed that tumor stage and operation type should be considered as the most important prognostic factors in patients with primary non-Hodgkin's lymphomas of the large bowel.
  • [MeSH-major] Colonic Neoplasms / diagnosis. Lymphoma, B-Cell / diagnosis. Rectal Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19069702.001).
  • [ISSN] 0354-950X
  • [Journal-full-title] Acta chirurgica Iugoslavica
  • [ISO-abbreviation] Acta Chir Iugosl
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Serbia
  •  go-up   go-down


15. Radman I, Kovacević-Metelko J, Aurer I, Nemet D, Zupancić-Salek S, Bogdanić V, Sertić D, Mrsić M, Pulanić R, Gasparović V, Labar B: Surgical resection in the treatment of primary gastrointestinal non-Hodgkin's lymphoma: retrospective study. Croat Med J; 2002 Oct;43(5):555-60
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical resection in the treatment of primary gastrointestinal non-Hodgkin's lymphoma: retrospective study.
  • AIM: To evaluate the role of surgical resection in the treatment of patients with primary gastrointestinal non-Hodgkin s lymphoma in our institution.
  • METHOD: The retrospective study included 79 patients with a histologically confirmed primary gastrointestinal lymphoma, who were diagnosed and treated for the disease in the 1978-1997 period.
  • According to the treatment modality, the patients were divided into surgically treated and surgically non-treated group.
  • RESULTS: The stomach was the primary site of non-Hodgkin s lymphoma in 45 (57%) patients, small intestine in 19 (24%), and colon in 9 (11%) patients.
  • Aggressive histology was found in 51 cases (65%), and low grade mucosa-associated lymphoid tissue (MALT) lymphoma in 28 (35%).
  • Helicobacter pylori infection was registered in 20 out of 45 patients with gastric lymphoma.
  • Twenty-six (33%) patients underwent surgical resection followed by chemotherapy, 47 (59%) were treated with chemotherapy alone, and 6 (8%) received antibiotics plus chemotherapy.
  • Patients with gastric lymphoma had better OS and EFS than patients with primary lymphoma at other sites (65% vs 42%, and 62 vs 28%, respectively) (p=0.005).
  • A 10-year EFS rates were 58% and 52% for surgically treated and non-treated group, respectively.
  • There was no significant difference between patients with resected and non-resected tumors (p=0.855).
  • CONCLUSION: Primary gastrointestinal lymphoma can be successfully treated with chemotherapy alone but surgery remains an important therapeutic option for emergency problems.
  • The main prognostic factors were primary tumor site and extent of the disease.
  • [MeSH-major] Colonic Neoplasms / surgery. Intestinal Neoplasms / surgery. Lymphoma, Non-Hodgkin / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Lymphoma, B-Cell, Marginal Zone / drug therapy. Lymphoma, B-Cell, Marginal Zone / surgery. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12402395.001).
  • [ISSN] 0353-9504
  • [Journal-full-title] Croatian medical journal
  • [ISO-abbreviation] Croat. Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Croatia
  •  go-up   go-down


16. Hokama A, Tomoyose T, Yamamoto Y, Watanabe T, Hirata T, Kinjo F, Kato S, Ohshima K, Uezato H, Takasu N, Fujita J: Adult T-cell leukemia/lymphoma presenting multiple lymphomatous polyposis. World J Gastroenterol; 2008 Nov 14;14(42):6584-8
MedlinePlus Health Information. consumer health - Colonic Polyps.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia/lymphoma presenting multiple lymphomatous polyposis.
  • Multiple lymphomatous polyposis (MLP) is an unusual form of non-Hodgkin's lymphoma characterized by polyps throughout the gastrointestinal tract.
  • It has been reported that most MLP are observed in cases with mantle cell lymphoma of B-cell type.
  • We herein present a case of a 66-year-old man with adult T-cell leukemia/lymphoma (ATLL).
  • Colonoscopy revealed MLP throughout the colon and histopathological findings of ATLL cell infiltration.
  • The patient died despite combination of chemotherapy.
  • The literature of manifestations of colonic involvement of ATLL is reviewed and the importance of endoscopic evaluation to differentiate ATLL intestinal lesions from opportunistic infectious enterocolitis is discussed.
  • [MeSH-major] Colonic Polyps / etiology. Intestinal Polyposis / etiology. Leukemia-Lymphoma, Adult T-Cell / complications
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols. Colonoscopy. Diagnosis, Differential. Fatal Outcome. Humans. Male. Middle Aged. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leuk Lymphoma. 1993 Oct;11(3-4):281-6 [8260899.001]
  • [Cites] World J Gastroenterol. 2008 Mar 21;14(11):1768-73 [18350608.001]
  • [Cites] Gastrointest Endosc. 2004 Feb;59(2):261 [14745401.001]
  • [Cites] Gastrointest Endosc. 2003 Nov;58(5):805-8 [14997894.001]
  • [Cites] J Gastroenterol. 2004 Aug;39(8):788-92 [15338374.001]
  • [Cites] Histopathology. 1984 Jul;8(4):641-56 [6479906.001]
  • [Cites] Cancer. 1988 Feb 15;61(4):824-8 [3257406.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • [Cites] Cancer. 1993 Feb 1;71(3):708-16 [8431850.001]
  • [Cites] Cancer. 1994 Dec 1;74(11):3042-50 [7954267.001]
  • [Cites] Cancer. 1996 Aug 1;78(3):396-402 [8697382.001]
  • [Cites] Endoscopy. 1995 Nov;27(9):700-3 [8903987.001]
  • [Cites] J Gastroenterol. 1997 Aug;32(4):553-7 [9250907.001]
  • [Cites] J Clin Immunol. 1999 May;19(3):186-93 [10404404.001]
  • [Cites] Cancer. 1961 Mar-Apr;14:249-57 [13695582.001]
  • [Cites] Gastrointest Endosc. 2004 Dec;60(6):983-4 [15605016.001]
  • [Cites] Histopathology. 2005 Nov;47(5):467-78 [16241994.001]
  • [Cites] Am J Trop Med Hyg. 2006 Feb;74(2):246-9 [16474078.001]
  • [Cites] Gut. 2006 Nov;55(11):1574, 1591 [17047108.001]
  • [Cites] Lancet Infect Dis. 2007 Apr;7(4):266-81 [17376384.001]
  • [Cites] Gastrointest Endosc. 2007 Apr;65(4):712-3 [17383471.001]
  • [Cites] Cancer Sci. 2007 Jun;98(6):772-8 [17388788.001]
  • [Cites] J Clin Pathol. 2007 Dec;60(12):1373-7 [18042693.001]
  • [Cites] J Clin Gastroenterol. 2001 Sep;33(3):241-6 [11500618.001]
  • (PMID = 19030219.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 24
  • [Other-IDs] NLM/ PMC2773353
  •  go-up   go-down


17. Gout PW, Buckley AR, Simms CR, Bruchovsky N: Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug. Leukemia; 2001 Oct;15(10):1633-40
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: a new action for an old drug.
  • Although cyst(e)ine is nutritionally a non-essential amino acid, lymphoid cells cannot synthesize it, rendering their growth dependent on uptake of cyst(e)ine from their microenvironment.
  • Accordingly, we previously suggested that the x(c)- plasma membrane cystine transporter provided a target for lymphoid cancer therapy.
  • Its inhibition could lead to cyst(e)ine deficiency in lymphoma cells via reduction of both their cystine uptake and cysteine supply by somatic cells.
  • In this study, using rat Nb2 lymphoma cultures, drugs were screened for growth arrest based on x(c)- inhibition.
  • It showed high rat lymphoma growth-inhibitory and lytic activity in vitro (IC50 = 0.16 mM), based specifically on inhibition of x(c)--mediated cystine uptake, in contrast to its colonic metabolites, sulfapyridine and 5-aminosalicylic acid.
  • Sulfasalazine was even more effective against human non-Hodgkin's lymphoma (DoHH2) cultures.
  • In rats (n = 13), sulfasalazine (i.p.) markedly inhibited growth of well-developed, rapidly growing rat Nb2 lymphoma transplants without apparent side-effects.
  • The x(c)- cystine transporter represents a novel target for sulfasalazine-like drugs with high potential for application in therapy of lymphoblastic and other malignancies dependent on extracellular cyst(e)ine.
  • [MeSH-major] Amino Acid Transport System y+. Anti-Inflammatory Agents, Non-Steroidal / pharmacology. Carrier Proteins / antagonists & inhibitors. Lymphoma / drug therapy. Sulfasalazine / pharmacology
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Cell Division / drug effects. Drug Evaluation, Preclinical. Humans. Inhibitory Concentration 50. Injections, Intraperitoneal. Neoplasm Transplantation. Rats. Rats, Inbred Strains. Tumor Cells, Cultured / drug effects

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. SULFASALAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11587223.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Grant] United States / NIDDK NIH HHS / DK / DK53452
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Amino Acid Transport System y+; 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Antineoplastic Agents; 0 / Carrier Proteins; 0 / SLC7A11 protein, human; 3XC8GUZ6CB / Sulfasalazine
  •  go-up   go-down


18. Tas F, Eralp Y, Basaran M, Sakar B, Alici S, Argon A, Bulutlar G, Camlica H, Aydiner A, Topuz E: Anemia in oncology practice: relation to diseases and their therapies. Am J Clin Oncol; 2002 Aug;25(4):371-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anemia in oncology practice: relation to diseases and their therapies.
  • Anemia is common in patients with cancer and is a frequent complication of myelosuppressive chemotherapy.
  • In this study, we investigated the incidence and severity of chemotherapy-induced anemia caused by the most common chemotherapy regimens, including the new generation of chemotherapeutic agents, used in the treatment of the major nonmyeloid malignancies in adults.
  • Five hundred fifty-two patients with histologically proven carcinoma originating from breast (n = 165), lung (n = 128), colon (n = 75), ovary (n = 84), and malignant lymphoma (n = 100) were included in this study.
  • Hemoglobin levels for each patient were measured with an automatic counter during both pretreatment and before each chemotherapy cycle during therapy.
  • Before chemotherapy, 44% of patients with breast carcinoma had anemia.
  • There was a 16% increase in the incidence of anemia after chemotherapy.
  • However, single-agent chemotherapy with newer generation caused more anemia when compared with the FAC regimen (p < 0.005).
  • Chemotherapy resulted in a significant decrease in hemoglobin levels when compared with pretreatment values in patients with lung cancer (p < 0.001).
  • During treatment, the increase in the incidence of grade II anemia was associated with a parallel decrease in the incidence of grade I anemia.
  • The incidence of anemia was equivalent in both patients with small-cell lung cancer and those with non-small-cell lung cancer treated with the etoposide and cisplatin (EP) combination.
  • Seventy-one percent of patients with colon cancer had anemia before initiation of chemotherapy.
  • Chemotherapy resulted in a prominent increase in incidence of anemia, which increased to 91.5%.
  • Less than 10% of patients developed severe anemia.
  • Showing a high incidence of anemia (82%) at presentation, hemoglobin levels in patients with malignant lymphoma were unaltered with chemotherapy.
  • There was a higher incidence of anemia in patients with non-Hodgkin's lymphoma receiving the cyclophosphamide, epirubicin, vincristine, prednisone (CEOP) regimen in contrast to patients with Hodgkin's lymphoma treated with the doxorubicin, bleomycin, vinblastine, dacarbazine (ABVD) combination.
  • In this study, we have observed equivalent rates of treatment-related anemia when compared with previous data in patients with specific tumor types.
  • [MeSH-major] Anemia / chemically induced. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Breast Neoplasms / drug therapy. Colonic Neoplasms / drug therapy. Female. Humans. Incidence. Lung Neoplasms / drug therapy. Lymphoma / drug therapy. Male. Middle Aged. Ovarian Neoplasms / drug therapy. Retrospective Studies. Risk Factors

  • Genetic Alliance. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Anemia.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12151968.001).
  • [ISSN] 0277-3732
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Isomoto H, Maeda T, Akashi T, Tsuchiya T, Kawaguchi Y, Sawayama Y, Koida S, Ohnita K, Kohno S, Tomonaga M: Multiple lymphomatous polyposis of the colon originating from T-cells: a case report. Dig Liver Dis; 2004 Mar;36(3):218-21
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple lymphomatous polyposis of the colon originating from T-cells: a case report.
  • Multiple lymphomatous polyposis is an unusual form of non-Hodgkin's lymphoma characterised by myriad polyps throughout the alimentary tract.
  • Most multiple lymphomatous polyposis cases are derived from B-cell, and there has been little information on multiple lymphomatous polyposis of T-cell origin.
  • Biopsy specimens showed diffuse proliferation of lymphoma cells negative for B-cell markers but positive for T-cell markers.
  • The patient was treated with combined chemotherapy, leading to complete resolution of the lesions.
  • [MeSH-major] Colonic Polyps / pathology. Colorectal Neoplasms / pathology. Lymphoma, T-Cell / pathology

  • MedlinePlus Health Information. consumer health - Colonic Polyps.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15046193.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


20. Wong MT, Eu KW: Primary colorectal lymphomas. Colorectal Dis; 2006 Sep;8(7):586-91
MedlinePlus Health Information. consumer health - Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary colorectal lymphomas.
  • OBJECTIVE: The incidence of primary colorectal lymphomas is rare, comprising 10-20% of gastrointestinal lymphomas and only 0.2-0.6% of large bowel malignancies.
  • Patients often present delayed with nonspecific symptoms and consequently have advanced disease at the time of diagnosis.
  • Treatment often involves a multimodality approach, combining surgery and chemotherapy, with the use of radiotherapy in selected cases.
  • We present our experience in the management of primary colorectal lymphomas over a 10-year period (1989-1999).
  • PATIENTS AND METHODS: We reviewed all cases of primary colorectal lymphoma seen at our institution from 1989 to 1999.
  • Patients were included based on standard diagnostic criteria for primary intestinal lymphoma established by Dawson in 1961.
  • The following clinical information was obtained: age, sex, presentation, site of tumour, operation performed, histology, length of stay, intraoperative complications, adjuvant therapy and duration of follow-up.
  • The type of lymphoma was classified according to the WHO classification system.
  • For staging, a modification of the Ann Arbor system for gastrointestinal lymphoma, proposed by Musshoff, was used.
  • RESULTS: During the 10-year period from 1989 to 1999, 14 cases of primary colorectal lymphomas were identified.
  • The two most common sites of involvement were the caecum (57.1%) and the rectum/sigmoid colon (21.4%).
  • The lesions manifested in a variety of ways, ranging from solitary fungating masses to multiple colonic polyps.
  • All cases were non-Hodgkin's B-cell lymphomas, with a majority being diffuse large B-cell lymphomas (57.1%).
  • Eleven patients (78.6%) received postoperative chemotherapy, with a regimen that included cyclophosphamide, vincristine, doxorubicin and prednisone.
  • CONCLUSION: Primary colorectal lymphoma is a rare condition.
  • Therapy usually involves resection of the affected colon and regional lymphovascular structures, followed by adjuvant chemotherapy, with a reported 5-year survival of 27-55%.
  • [MeSH-major] Colorectal Neoplasms. Lymphoma

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16919111.001).
  • [ISSN] 1462-8910
  • [Journal-full-title] Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland
  • [ISO-abbreviation] Colorectal Dis
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 29
  •  go-up   go-down


21. Vardy J, Wong E, Izard M, Clifford A, Clarke SJ: Life-threatening anaphylactoid reaction to amifostine used with concurrent chemoradiotherapy for nasopharyngeal cancer in a patient with dermatomyositis: a case report with literature review. Anticancer Drugs; 2002 Mar;13(3):327-30
Hazardous Substances Data Bank. AMIFOSTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most common associated cancers are ovarian, lung, pancreatic, stomach, colon and non-Hodgkin's lymphoma.
  • Radiotherapy is the mainstay of treatment for early nasopharyngeal cancer, but combination chemoradiotherapy is becoming more common for patients with advanced disease since the Intergroup trial 0099 demonstrated improved progression-free survival and overall survival for chemoradiotherapy.
  • [MeSH-major] Amifostine / adverse effects. Anaphylaxis / chemically induced. Dermatomyositis / drug therapy. Dermatomyositis / radiotherapy. Nasopharyngeal Neoplasms / drug therapy. Nasopharyngeal Neoplasms / radiotherapy. Radiation-Protective Agents / adverse effects
  • [MeSH-minor] Combined Modality Therapy. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Dermatomyositis.
  • MedlinePlus Health Information. consumer health - Anaphylaxis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11984077.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Radiation-Protective Agents; M487QF2F4V / Amifostine
  • [Number-of-references] 7
  •  go-up   go-down


22. O'Mahony D, Morris JC, Quinn C, Gao W, Wilson WH, Gause B, Pittaluga S, Neelapu S, Brown M, Fleisher TA, Gulley JL, Schlom J, Nussenblatt R, Albert P, Davis TA, Lowy I, Petrus M, Waldmann TA, Janik JE: A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy. Clin Cancer Res; 2007 Feb 1;13(3):958-64
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The primary end point was to determine drug toxicity.
  • EXPERIMENTAL DESIGN: Three patients with colon cancer, four with non-Hodgkin's lymphoma, and four with prostate cancer were treated.
  • RESULTS: Tumor regression was observed in two patients with lymphoma; one of which obtained a partial response of 14-month duration.
  • One drug-related grade 3 toxicity was observed.
  • One patient died within 30 days of treatment due to progressive colon cancer.
  • No increase in vaccine-specific T-cell responses was observed after therapy.
  • Tregs as detected by expression of CD4+CD25+CD62L+ declined at early time points but rebounded to levels at or above baseline values at the time of the next infusion.
  • CONCLUSIONS: Ipilimumab treatment depressed Treg numbers at early time points in the treatment cycle but was not accompanied by an increase in vaccine-specific CD8+ T-cell responses in these patients previously treated with a variety of investigational anticancer vaccines.
  • A partial response was observed in one patient with follicular lymphoma.
  • A phase I/II trial evaluating ipilimumab in patients with follicular lymphoma is currently ongoing.
  • [MeSH-major] Antigens, CD / metabolism. Antigens, Differentiation / metabolism. Cancer Vaccines. Colonic Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Prostatic Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Cancer Res. 2007 Feb 1;13(3):785-8 [17289867.001]
  • (PMID = 17289891.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Grant] United States / Intramural NIH HHS / /
  • [Publication-type] Journal Article; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Differentiation; 0 / Antineoplastic Agents; 0 / CTLA-4 Antigen; 0 / CTLA4 protein, human; 0 / Cancer Vaccines; 0 / Interleukin-2 Receptor alpha Subunit; 126880-86-2 / L-Selectin; EC 3.4.21.77 / Prostate-Specific Antigen
  •  go-up   go-down


23. DeNardo SJ, Denardo GL: Targeted radionuclide therapy for solid tumors: an overview. Int J Radiat Oncol Biol Phys; 2006;66(2 Suppl):S89-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Targeted radionuclide therapy for solid tumors: an overview.
  • Although radioimmunotherapy (RIT) has been effective in non-Hodgkin's lymphoma (NHL) as a single agent, solid tumors have shown less clinically significant therapeutic response to RIT alone.
  • The clinical impact of RIT or other forms of targeted radionuclide therapy for solid tumors depends on the development of a high therapeutic index (TI) for the tumor vs. normal tissue effect, and the implementation of RIT as part of synergistic combined modality therapy (CMRIT).
  • Evidence suggests that combination and sequencing of RIT in CMRIT appropriately can provide effective treatment for many solid tumors.
  • Vascular targets provide RIT enhancement opportunities and nanoparticles may prove to be effective carriers for RIT combined with intracellular drug delivery or alternating magnetic frequency (AMF) induced thermal tumor necrosis.
  • The sequence and timing of combined modality treatments will be of critical importance to achieve synergy for therapy while minimizing toxicity.
  • This can be readily accomplished clinically using quantitative high-resolution imaging (e.g., positron emission tomography [PET]).
  • [MeSH-minor] Breast Neoplasms / radiotherapy. Colonic Neoplasms / radiotherapy. Female. Humans. Male. Prostatic Neoplasms / radiotherapy. Radiotherapy Dosage

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16979448.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P01 CA47829
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Review
  • [Publication-country] United States
  • [Number-of-references] 89
  •  go-up   go-down


24. Osorio S, Bernis C, de La Cámara R: Lactic Acidosis in Non-Hodgkin's Lymphoma and response to Chemotherapy. Haematologica; 2002 Feb;87(2):ELT05
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lactic Acidosis in Non-Hodgkin's Lymphoma and response to Chemotherapy.
  • [MeSH-major] Acidosis, Lactic / etiology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large B-Cell, Diffuse / complications
  • [MeSH-minor] Adenocarcinoma. Aged. Bleomycin / administration & dosage. Colonic Neoplasms. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Fatal Outcome. Humans. Lactates / blood. Liver / pathology. Male. Neoplasms, Second Primary. Prednisone / administration & dosage. Sodium Bicarbonate / therapeutic use. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Lactic Acidosis.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. SODIUM BICARBONATE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11836182.001).
  • [ISSN] 0390-6078
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Lactates; 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8MDF5V39QO / Sodium Bicarbonate; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; VACOP-B protocol
  •  go-up   go-down


25. Dalal L: Primary multifocal non-Hodgkin lymphoma of the colon successfully treated with chemotherapy. Gastrointest Endosc; 2008 Nov;68(5):1005-6; discussion 1006
Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary multifocal non-Hodgkin lymphoma of the colon successfully treated with chemotherapy.
  • [MeSH-major] Colonic Neoplasms / drug therapy. Lymphoma, Follicular / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Colonoscopy. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18565526.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down






Advertisement